Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 65 | 5,206 | 48% |
| 2020 | 50 | 4,365 | 50% |
| 2021 | 52 |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 39% of the cases CMS names in California; 39 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 38 | 2,602+2%/yr | +2%/yr | 3.5 | 38% | 2,760 in 2030+1%/yr |
| Washington | 18 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 202 | 14,148−8%/yr | −8%/yr | 4.20.8× | 48% | 14,100 in 2030−0.1%/yr |
| Kidney stone management |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
| 2024 |
| 5,242 |
| 56% |
| 2025 est. | ≈ 5,450 | – |
| 2026 est. | ≈ 5,590 | – |
| 4,890 |
| 52% |
| 2022 | 62 | 5,116 | 53% |
| 2023 | 68 | 5,441 | 55% |
| 2024 | 73 | 5,242 | 56% |
| 2025 from claims | – | 5,446 4,998–5,762 | 56% |
| 2026 forecast | – | 5,590 4,919–6,451 | 56% |
| 2027 forecast | – | 5,707 4,879–6,801 | 56% |
| 2028 forecast | – | 5,826 4,861–7,133 | 56% |
| 2029 forecast | – | 5,947 4,857–7,458 | 57% |
| 2030 forecast | – | 6,070 4,863–7,779 | 57% |
In 2025, 2% inpatient hospital, 78% hospital outpatient, 20% surgery center. The share outside the hospital has moved +9 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 1,306−6.4%/yr |
| −6.4%/yr |
| 1.7 |
| 6% |
| 1,360 in 2030+0.7%/yr |
| Colorado | 21 | 1,253+1.4%/yr | +1.4%/yr | 2.6 | 19% | 1,570 in 2030+3.8%/yr |
| Oregon | 11 | 883−0.6%/yr | −0.6%/yr | 2.1 | 21% | 1,300 in 2030+6.6%/yr |
| Nevada | 8 | 631−0.3%/yr | −0.3%/yr | 2.2 | 19% | 1,080 in 2030+9.3%/yr |
| Utah | 6 | 487−2.4%/yr | −2.4%/yr | 2.2 | 7% | 610 in 2030+3.9%/yr |
| Idaho | 4 | 408+1.3%/yr | +1.3%/yr | 2.0 | 11% | 900 in 2030+14%/yr |
| Montana | 6 | 361+0.1%/yr | +0.1%/yr | 1.9 | 0% | 370 in 2030+0.3%/yr |
| New Mexico | 2 | 167−7.1%/yr | −7.1%/yr | 0.7 | 9% | 240 in 2030+6.5%/yr |
| Hawaii | 4 | 114−4.8%/yr | −4.8%/yr | 0.9 | 0% | 260 in 2030+15%/yr |
| Alaska | 2 | 107−0.7%/yr | −0.7%/yr | 0.9 | 0% | 90 in 2030−2.7%/yr |
| 210 |
| 10,020+0.3%/yr |
| +0.3%/yr |
| 3.00.7× |
| 17% |
| 11,600 in 2030+2.5%/yr |
| Hysterectomy, hysteroscopy & ablation | 85 | 6,904+1.6%/yr | +1.6%/yr | 2.30.9× | 25% | 7,960 in 2030+2.4%/yr |
| Prostatectomy & nephrectomy | 71 | 3,581+0.9%/yr | +0.9%/yr | 1.21.0× | 0% | 4,490 in 2030+3.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 69% of company spending on these surgeons in 2025, +2 pts on 2024.
In 2025, 14 companies reported engagement with California’s surgeons worth $946K in consulting, speaking, meals and travel tied to these products, about $13K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.